Pandemic XXXX (H1N1) 2009 in India: duration of @entity778 in patients under antiviral treatment.

@entity1 @entity778 @entity1707 @entity684 @entity683 @entity1800 @entity281
BACKGROUND: National Centre for Disease Control (NCDC), Delhi, is a national nodal centre for surveillance of pandemic @entity683 (H1N1) in India. The present study was undertaken to see the period of infectivity in positive cases undergoing antiviral therapy. OBJECTIVE: To assess the duration of @entity778 by real-time polymerase chain reaction (real-time PCR) in some of the positive @entity1 taking @entity684 treatment. MATERIALS AND METHODS: Clinical samples (throat swabs, nasal swabs and nasopharyngeal swabs) collected by the clinicians from @entity1 quarantined in government hospitals in different parts of India are being sent to the designated reference laboratory at Delhi for screening presence of @entity778 . The samples are tested by Real-Time PCR using CDC recommended reagents and protocol for confirmation of the H1N1 novel influenza @entity778 . In 150 of the positive cases, we requested the clinicians to send samples for 5 consecutive days after administration of antiviral therapy, to see the trend of therapy response on @entity1800 . Samples for more than 5 days were received from @entity1 till they showed no amplification for any of the three target genes ( @entity683 , @entity1707 @entity683 or @entity1707 H1). RESULTS AND CONCLUSION: In 99.33% (149/150) cases, the @entity281 resolved within 10 days. Sixty-four percent (96/150) of the positive @entity1 turned negative within 5 days of the start of antiviral treatment. Only one @entity1 belonging to high risk group showed prolonged @entity778 (19 days).
